FuelCell Energy Inc vs Zimmer Biomet Holdings Inc — how do they compare? FuelCell Energy Inc trades at $18.61 (market cap $1.62B), while Zimmer Biomet Holdings Inc trades at $92.97 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 10.8× FuelCell Energy Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | ZBH | |
|---|---|---|
Market Cap | $1.62B | $17.44B |
Sector | Industrials | Health |
52-Week High | $36.01 | $107.71 |
52-Week Low | $3.92 | $79.58 |
Enterprise Value | $1.47B | $24.49B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $21.35, up 11.9% in the last 24 hours, reflecting high volatility amid recent news. The stock shows a neutral technical signal with bearish moving averages, while fundamentals reveal persistent losses with a net income margin of -132.41% in 2025 despite revenue growth to $158.16M. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225M stock offering that caused temporary dilution concerns.
The outlook is mixed: analyst consensus is balanced with a $20.75 price target, but continued cash burn and high valuation multiples pose risks. Opportunities lie in AI-driven data center demand, though profitability remains a key challenge for sustainable upside.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Trailing returns across standard periods
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →